{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:36:54Z","timestamp":1787495814229,"version":"build-2736575974"},"reference-count":131,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.blre.2023.101143","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T18:47:02Z","timestamp":1700506022000},"page":"101143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era"],"prefix":"10.1016","volume":"64","author":[{"given":"Joaqu\u00edn","family":"Jerez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.blre.2023.101143_bb0005","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.blre.2023.101143_bb0010","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.blre.2023.101143_bb0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101143_bb0020","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0025","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2023.101143_bb0030","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia."},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0035","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood."},{"issue":"22","key":"10.1016\/j.blre.2023.101143_bb0040","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2015-04-641100","article-title":"Genomic analysis of germ line and somatic variants in familial myelodysplasia\/acute myeloid leukemia","volume":"126","author":"Churpek","year":"2015","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101143_bb0045","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2021011354","article-title":"Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML","volume":"139","author":"Yang","year":"2022","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2023.101143_bb0050","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1182\/blood.2022015790","article-title":"Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages","volume":"140","author":"Feurstein","year":"2022","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101143_bb0055","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/s41375-021-01137-0","article-title":"Germline variants drive myelodysplastic syndrome in young adults","volume":"35","author":"Feurstein","year":"2021","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101143_bb0060","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/leu.2017.28","article-title":"Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome\/acute leukemia predisposition syndromes","volume":"31","author":"Guidugli","year":"2017","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2023.101143_bb0065","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clml.2016.04.001","article-title":"Evaluation of patients and families with concern for predispositions to hematologic malignancies within the hereditary hematologic malignancy clinic (HHMC)","volume":"16","author":"DiNardo","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.blre.2023.101143_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.03.021","article-title":"Germline genetic IKZF1 variation and predisposition to childhood acute lymphoblastic leukemia","volume":"33","author":"Churchman","year":"2018","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.blre.2023.101143_bb0075","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/ng.2754","article-title":"A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia","volume":"45","author":"Shah","year":"2013","journal-title":"Nat Genet"},{"issue":"7","key":"10.1016\/j.blre.2023.101143_bb0080","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/bloodadvances.2018030635","article-title":"Germline deletion of ETV6 in familial acute lymphoblastic leukemia","volume":"3","author":"Rampersaud","year":"2019","journal-title":"Blood Adv"},{"issue":"13","key":"10.1016\/j.blre.2023.101143_bb0085","doi-asserted-by":"crossref","first-page":"1120829","DOI":"10.3389\/fonc.2023.1120829","article-title":"Hereditary predisposition to malignant myeloid hemopathies: caution in use of saliva and guideline based on our experience","author":"Perani","year":"2023","journal-title":"Front Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101143_bb0090","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/humu.24374","article-title":"Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders","volume":"43","author":"DeRoin","year":"2022","journal-title":"Hum Mutat"},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0095","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/ajh.26321","article-title":"Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes","volume":"96","author":"Martin","year":"2021","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0100","doi-asserted-by":"crossref","first-page":"13751","DOI":"10.1038\/s41598-018-31503-5","article-title":"Efficient identification of somatic mutations in acute myeloid leukaemia using whole exome sequencing of fingernail derived DNA as germline control","volume":"8","author":"Kakadia","year":"2018","journal-title":"Sci Rep"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101143_bb0105","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/blood-2021-154007","article-title":"Utilization of non-invasive sample sources for identification of somatic and germline mutations in hematologic malignancies and clonal hematopoiesis","volume":"138","author":"Soyfer","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0110","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/bjh.18675","article-title":"Germline predisposition to haematological malignancies: best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group","volume":"201","author":"Speight","year":"2023","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.blre.2023.101143_bb0115","doi-asserted-by":"crossref","first-page":"1084736","DOI":"10.3389\/fonc.2023.1084736","article-title":"Prioritization of patients for germline testing based on tumor profiling of hematopoietic malignancies","author":"Godley","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101143_bb0120","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1111\/bjh.16322","article-title":"In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation","volume":"188","author":"Hockings","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101143_bb0125","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000321","article-title":"Nordic guidelines for germline predisposition to myeloid neoplasms in adults: recommendations for genetic diagnosis, clinical management and follow-up","volume":"3","author":"Baliakas","year":"2019","journal-title":"Hemasphere."},{"key":"10.1016\/j.blre.2023.101143_bb0130","series-title":"NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndrome","author":"NCCN. National Comprehensive Cancer Network (NCCN)","year":"2023"},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0135","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41436-020-0934-y","article-title":"Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies","volume":"23","author":"Roloff","year":"2021","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.blre.2023.101143_bb0140","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101143_bb0145","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.gim.2021.12.008","article-title":"A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias","volume":"24","author":"Feurstein","year":"2022","journal-title":"Genet Med"},{"issue":"12","key":"10.1016\/j.blre.2023.101143_bb0150","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101143_bb0155","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s41375-023-01955-4","article-title":"Needle in a haystack or elephant in the room? Identifying germline predisposition syndromes in the setting of a new myeloid malignancy diagnosis","volume":"37","author":"Reinig","year":"2023","journal-title":"Leukemia."},{"issue":"4","key":"10.1016\/j.blre.2023.101143_bb0160","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s11899-021-00636-2","article-title":"The emerging role of hematopathologists and molecular pathologists in detection, monitoring, and management of myeloid neoplasms with germline predisposition","volume":"16","author":"Kanagal-Shamanna","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0165","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.bbmt.2016.08.002","article-title":"Identifying inherited and acquired genetic factors involved in poor stem cell mobilization and donor-derived malignancy","volume":"22","author":"Rojek","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0170","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1038\/s41375-021-01246-w","article-title":"Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer","volume":"35","author":"Singhal","year":"2021","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.blre.2023.101143_bb0175","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.29615","article-title":"Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia","volume":"122","author":"Churpek","year":"2016","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.blre.2023.101143_bb0180","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","article-title":"Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary Cancer syndrome","volume":"7","author":"Samadder","year":"2021","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101143_bb0185","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jamaoncol.2021.1012","article-title":"Universal genetic testing to identify pathogenic germline variants in patients with Cancer-reply","volume":"7","author":"Esplin","year":"2021","journal-title":"JAMA Oncol"},{"issue":"20","key":"10.1016\/j.blre.2023.101143_bb0190","doi-asserted-by":"crossref","first-page":"R225","DOI":"10.1093\/hmg\/ddab141","article-title":"Germline predisposition to hematopoietic malignancies","volume":"30","author":"Feurstein","year":"2021","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1016\/j.blre.2023.101143_bb0195","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2017-02-735290","article-title":"Genetic predisposition to hematologic malignancies: management and surveillance","volume":"130","author":"Godley","year":"2017","journal-title":"Blood."},{"issue":"9","key":"10.1016\/j.blre.2023.101143_bb0200","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.mayocp.2019.04.007","article-title":"Clinical applications and utility of a precision medicine approach for patients with unexplained cytopenias","volume":"94","author":"Mangaonkar","year":"2019","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0205","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13696998.2022.2152233","article-title":"A review of the cost-effectiveness of genetic testing for germline variants in familial cancer","volume":"26","author":"Teppala","year":"2023","journal-title":"J Med Econ"},{"issue":"21","key":"10.1016\/j.blre.2023.101143_bb0210","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood.2022015853","article-title":"Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia","volume":"140","author":"Duncavage","year":"2022","journal-title":"Blood."},{"issue":"19","key":"10.1016\/j.blre.2023.101143_bb0215","doi-asserted-by":"crossref","first-page":"4798","DOI":"10.1182\/bloodadvances.2020002803","article-title":"Multiple donor-derived leukemias in a recipient of allogeneic hematopoietic cell transplantation for myeloid malignancy","volume":"4","author":"Aldoss","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2023.101143_bb0220","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.bbmt.2006.01.006","article-title":"Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation","volume":"12","author":"Sala-Torra","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.blre.2023.101143_bb0225","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/s41375-018-0218-6","article-title":"Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. European experience and risk factor analysis of donor cell-derived leukaemias\/MDS following haematopoietic cell transplantation","volume":"33","author":"Engel","year":"2019","journal-title":"Leukemia."},{"issue":"8","key":"10.1016\/j.blre.2023.101143_bb0230","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1007\/s00277-017-3041-7","article-title":"Disease-specific hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes","volume":"96","author":"Li","year":"2017","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0235","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1080\/16078454.2021.1876393","article-title":"Hematopoietic stem cell transplantation for inherited bone marrow failure syndromes: alternative donor and disease-specific conditioning regimen with unmanipulated grafts","volume":"26","author":"Lu","year":"2021","journal-title":"Hematology."},{"issue":"12","key":"10.1016\/j.blre.2023.101143_bb0240","article-title":"Adult-onset hereditary myeloid malignancy and allogeneic stem cell transplantation","author":"Toya","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101143_bb0245","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/bloodadvances.2022008172","article-title":"Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies","volume":"7","author":"Saygin","year":"2023","journal-title":"Blood Adv"},{"issue":"25","key":"10.1016\/j.blre.2023.101143_bb0250","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"BMT CTN 1703 investigators. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101143_bb0255","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11899-023-00694-8","article-title":"Managing survivorship after hematopoietic cell transplantation","volume":"18","author":"Khera","year":"2023","journal-title":"Curr Hematol Malig Rep"},{"issue":"9","key":"10.1016\/j.blre.2023.101143_bb0260","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbmt.2017.05.022","volume":"23","author":"Dietz","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.blre.2023.101143_bb0265","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11899-022-00667-3","article-title":"Germline and somatic defects in DDX41 and its impact on myeloid neoplasms","volume":"17","author":"Badar","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"issue":"17","key":"10.1016\/j.blre.2023.101143_bb0270","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood.2019000909","article-title":"Germline DDX41 mutations define a significant entity within adult MDS\/AML patients","volume":"134","author":"S\u00e9bert","year":"2019","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2023.101143_bb0275","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germ line DDX41 mutations define a unique subtype of myeloid neoplasm","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood."},{"issue":"13","key":"10.1016\/j.blre.2023.101143_bb0280","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood.2022017715","article-title":"DDX41-associated susceptibility to myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2023.101143_bb0285","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/ajh.25486","article-title":"DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease","volume":"94","author":"Quesada","year":"2019","journal-title":"Am J Hematol"},{"issue":"14","key":"10.1016\/j.blre.2023.101143_bb0290","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood.2023020209","article-title":"Prevalence and significance of DDX41 gene variants in the general population","volume":"142","author":"Cheloor Kovilakam","year":"2023","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101143_bb0295","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41375-021-01404-0","article-title":"AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome","volume":"36","author":"Li","year":"2022","journal-title":"Leukemia."},{"issue":"5","key":"10.1016\/j.blre.2023.101143_bb0300","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","article-title":"Inherited and somatic defects in DDX41 in myeloid neoplasms","volume":"27","author":"Polprasert","year":"2015","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.blre.2023.101143_bb0305","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/leu.2016.228","article-title":"Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide","volume":"30","author":"Negoro","year":"2016","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.blre.2023.101143_bb0310","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajh.25610","article-title":"Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation","volume":"95","author":"Abou Dalle","year":"2020","journal-title":"Am J Hematol"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2023.101143_bb0315","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2018-99-114681","article-title":"Genomic biomarkers predict response\/resistance to lenalidomide in non-del(5q) myelodysplastic syndromes","volume":"132","author":"Madanat","year":"2018","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101143_bb0320","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/bloodadvances.2021005738","article-title":"Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms","volume":"6","author":"Alkhateeb","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0325","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41408-023-00818-6","article-title":"Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome","volume":"13","author":"Al-Kali","year":"2023","journal-title":"Blood Cancer J"},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0330","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/ajh.27070","article-title":"Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants","volume":"98","author":"Bataller","year":"2023","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0335","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41375-023-01999-6","article-title":"Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients","volume":"37","author":"Jahn","year":"2023","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.blre.2023.101143_bb0340","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evid"},{"issue":"7","key":"10.1016\/j.blre.2023.101143_bb0345","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1182\/blood.2021015135","article-title":"The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms","volume":"140","author":"Li","year":"2022","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0350","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/s41409-022-01776-6","article-title":"Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia","volume":"57","author":"Baranwal","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.blre.2023.101143_bb0355","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2021015328","article-title":"Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study","volume":"140","author":"Duployez","year":"2022","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0360","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41408-023-00846-2","article-title":"DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation","volume":"13","author":"Rolles","year":"2023","journal-title":"Blood Cancer J"},{"issue":"4","key":"10.1016\/j.blre.2023.101143_bb0365","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/leu.2017.44","article-title":"Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation","volume":"31","author":"Kobayashi","year":"2017","journal-title":"Leukemia."},{"issue":"4","key":"10.1016\/j.blre.2023.101143_bb0370","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11899-022-00663-7","article-title":"Germline CHEK2 and ATM variants in myeloid and other hematopoietic malignancies","volume":"17","author":"Stubbins","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0375","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/jmedgenet-2019-106189","article-title":"One in three highly selected Greek patients with breast cancer carries a loss-of- function variant in a cancer susceptibility gene","volume":"57","author":"Fostira","year":"2020","journal-title":"J Med Genet"},{"issue":"5","key":"10.1016\/j.blre.2023.101143_bb0380","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2023.101143_bb0385","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1001\/jamaoncol.2018.1986","article-title":"Prevalence of germline mutations in cancer susceptibility genes in patients with advanced renal cell carcinoma","volume":"4","author":"Carlo","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7831","key":"10.1016\/j.blre.2023.101143_bb0390","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature."},{"issue":"7831","key":"10.1016\/j.blre.2023.101143_bb0395","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-020-2786-7","article-title":"Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells","volume":"586","author":"Bao","year":"2020","journal-title":"Nature."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101143_bb0400","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2020-140868","article-title":"Contributions to clonal hematopoiesis in solid cancer patients","volume":"136","author":"Franch-Exp\u00f3sito","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0405","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/bjh.13559","article-title":"The germline mutations of the CHEK2 gene are associated with an increased risk of polycythaemia vera","volume":"173","author":"Janiszewska","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101143_bb0410","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3324\/haematol.2011.049494","article-title":"A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations","volume":"97","author":"Janiszewska","year":"2012","journal-title":"Haematologica."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101143_bb0415","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1182\/blood-2022-158799","article-title":"Characteristics of germline CHEK2 mutated patients in a large cohort of 2322 myeloid malignancies","volume":"140","author":"Freiman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101143_bb0420","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.leukres.2018.05.013","article-title":"Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML","volume":"70","author":"Janiszewska","year":"2018","journal-title":"Leuk Res"},{"issue":"4","key":"10.1016\/j.blre.2023.101143_bb0425","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1200\/JCO.2007.12.5922","article-title":"CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls","volume":"26","author":"Weischer","year":"2008","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2023.101143_bb0430","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamaoncol.2021.6204","volume":"8","author":"Lowry","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.blre.2023.101143_bb0435","series-title":"NCCN Clinical Practice Guidelines in Oncology. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic","author":"NCCN. National Comprehensive Cancer Network (NCCN)","year":"2023"},{"issue":"17","key":"10.1016\/j.blre.2023.101143_bb0440","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1016\/j.ejca.2011.03.025","article-title":"Meta-analysis of CHEK2 1100delC variant and colorectal cancer susceptibility","volume":"47","author":"Xiang","year":"2011","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0445","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/gim.2018.12","article-title":"A counseling framework for moderate-penetrance colorectal cancer susceptibility genes","volume":"20","author":"Katona","year":"2018","journal-title":"Genet Med"},{"key":"10.1016\/j.blre.2023.101143_bb0450","series-title":"NCCN Clinical Practice Guidelines in Oncology. Genetic\/Familial High-Risk Assessment: Colorectal","author":"NCCN. National Comprehensive Cancer Network (NCCN)","year":"2023"},{"issue":"13","key":"10.1016\/j.blre.2023.101143_bb0455","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2022017735","article-title":"Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26","volume":"141","author":"Homan","year":"2023","journal-title":"Blood."},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2023.101143_bb0460","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/ijlh.12999","article-title":"Inherited thrombocytopenia and platelet disorders with germline predisposition to myeloid neoplasia","volume":"41","author":"Galera","year":"2019","journal-title":"Int J Lab Hematol"},{"issue":"21","key":"10.1016\/j.blre.2023.101143_bb0465","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/blood.2019003357","article-title":"High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML","volume":"135","author":"Simon","year":"2020","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.blre.2023.101143_bb0470","doi-asserted-by":"crossref","first-page":"E86","DOI":"10.1002\/ajh.24703","article-title":"Mutations of RUNX1 in families with inherited thrombocytopenia","volume":"92","author":"De Rocco","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2023.101143_bb0475","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13023-016-0432-0","article-title":"Haematological spectrum and genotype-phenotype correlations in nine unrelated families with RUNX1 mutations from the French network on inherited platelet disorders","volume":"11","author":"Latger-Cannard","year":"2016","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0480","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.2019000937","article-title":"Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)","volume":"136","author":"Brown","year":"2020","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0485","doi-asserted-by":"crossref","first-page":"E313","DOI":"10.1002\/ajh.25965","article-title":"Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations","volume":"95","author":"Lachowiez","year":"2020","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101143_bb0490","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/bloodadvances.2019000901","article-title":"RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML","volume":"4","author":"Brown","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.blre.2023.101143_bb0495","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1038\/s41375-020-0752-x","article-title":"Spectrum of abnormalities and clonal transformation in germline RUNX1 familial platelet disorder and a genomic comparative analysis with somatic RUNX1 mutations in MDS\/MPN overlap neoplasms","volume":"34","author":"DiFilippo","year":"2020","journal-title":"Leukemia."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101143_bb0500","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2022-167600","article-title":"Somatic mutational landscape of hereditary hematopoietic malignancies associated with germline variants in RUNX1, GATA2 and DDX41","volume":"140","author":"Brown","year":"2022","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.blre.2023.101143_bb0505","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1200\/JCO.2010.30.7926","article-title":"RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group","volume":"29","author":"Gaidzik","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.blre.2023.101143_bb0510","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1182\/blood-2009-05-223784","article-title":"AML1\/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations","volume":"114","author":"Tang","year":"2009","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2023.101143_bb0515","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/ajh.26724","article-title":"Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia","volume":"97","author":"Venugopal","year":"2022","journal-title":"Am J Hematol"},{"issue":"24","key":"10.1016\/j.blre.2023.101143_bb0520","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.blre.2023.101143_bb0525","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1080\/14728222.2021.1915991","article-title":"Targeting RUNX1 in acute myeloid leukemia: preclinical innovations and therapeutic implications","volume":"25","author":"Gonzales","year":"2021","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0530","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.2018893982","article-title":"RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1","volume":"134","author":"Mill","year":"2019","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2023.101143_bb0535","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1182\/blood-2008-05-156745","article-title":"Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy","volume":"112","author":"Owen","year":"2008","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101143_bb0540","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/bjh.13317","article-title":"Haematopoietic and immune defects associated with GATA2 mutation","volume":"169","author":"Collin","year":"2015","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.blre.2023.101143_bb0545","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/bjh.18330","article-title":"GATA2 deficiency and MDS\/AML: experimental strategies for disease modelling and future therapeutic prospects","volume":"199","author":"Kotmayer","year":"2022","journal-title":"Br J Haematol"},{"issue":"13","key":"10.1016\/j.blre.2023.101143_bb0550","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood.2022017764","article-title":"The spectrum of GATA2 deficiency syndrome","volume":"141","author":"Calvo","year":"2023","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0555","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/blood.2019000937","article-title":"Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA)","volume":"136","author":"Brown","year":"2020","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2023.101143_bb0560","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2011-05-356352","article-title":"Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome","volume":"118","author":"Hsu","year":"2011","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101143_bb0565","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1084\/jem.20101459","article-title":"The human syndrome of dendritic cell, monocyte, B and NK lymphoid deficiency","volume":"208","author":"Bigley","year":"2011","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.blre.2023.101143_bb0570","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/ng.913","article-title":"Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia","volume":"43","author":"Hahn","year":"2011","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.blre.2023.101143_bb0575","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1002\/ajmg.a.33445","article-title":"Emberger syndrome\u2014primary lymphedema with myelodysplasia: report of seven new cases","volume":"152A","author":"Mansour","year":"2010","journal-title":"Am J Med Genet"},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0580","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/humu.24271","article-title":"GATA2 deficiency syndrome: a decade of discovery","volume":"42","author":"Homan","year":"2021","journal-title":"Hum Mutat"},{"issue":"11","key":"10.1016\/j.blre.2023.101143_bb0585","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/blood-2015-09-669937","article-title":"EWOG-MDS. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents","volume":"127","author":"Wlodarski","year":"2016","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.blre.2023.101143_bb0590","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1182\/bloodadvances.2021005065","article-title":"ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome","volume":"6","author":"West","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.blre.2023.101143_bb0595","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3390\/cancers15051590","article-title":"The clinical spectrum, diagnosis, and management of GATA2 deficiency","volume":"15","author":"Santiago","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.blre.2023.101143_bb0600","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3324\/haematol.2017.181909","article-title":"French GATA2 study group. Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients","volume":"103","author":"Donadieu","year":"2018","journal-title":"Haematologica."},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0605","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/bjh.17840","article-title":"Donor source and post-transplantation cyclophosphamide influence outcome in allogeneic stem cell transplantation for GATA2 deficiency","volume":"196","author":"Nichols-Vinueza","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.blre.2023.101143_bb0610","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bbmt.2018.01.030","article-title":"Allogeneic hematopoietic stem cell transplantation for GATA2 deficiency using a Busulfan-based regimen","volume":"24","author":"Parta","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.blre.2023.101143_bb0615","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.bbmt.2020.02.015","article-title":"Comparison of outcomes of Myeloablative allogeneic stem cell transplantation for pediatric patients with bone marrow failure, myelodysplastic syndrome and acute myeloid leukemia with and without germline GATA2 mutations","volume":"26","author":"Hofmann","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"10.1016\/j.blre.2023.101143_bb0620","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood-2018-07-861070","article-title":"Donor-derived MDS\/AML in families with germline GATA2 mutation","volume":"132","author":"Galera","year":"2018","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.blre.2023.101143_bb0625","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa041331","article-title":"Mutation of CEBPA in familial acute myeloid leukemia","volume":"351","author":"Smith","year":"2004","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.blre.2023.101143_bb0630","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1182\/blood.2020009680","article-title":"Et al; study Alliance leukemia (SAL). CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome","volume":"139","author":"Taube","year":"2022","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101143_bb0635","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","article-title":"Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity","volume":"117","author":"Taskesen","year":"2011","journal-title":"Blood."},{"issue":"8","key":"10.1016\/j.blre.2023.101143_bb0640","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2010-09-307280","volume":"117","author":"Pabst","year":"2011","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.blre.2023.101143_bb0645","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101143_bb0650","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1053\/j.seminhematol.2017.04.001","article-title":"Familial CEBPA-mutated acute myeloid leukemia","volume":"54","author":"Tawana","year":"2017","journal-title":"Semin Hematol"},{"issue":"19","key":"10.1016\/j.blre.2023.101143_bb0655","doi-asserted-by":"crossref","first-page":"5257","DOI":"10.1182\/blood-2010-12-326322","article-title":"First report of multiple CEBPA mutations contributing to donor origin of leukemia relapse after allogeneic hematopoietic stem cell transplantation","volume":"117","author":"Xiao","year":"2011","journal-title":"Blood."}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23001042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:31:18Z","timestamp":1759437078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23001042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":131,"alternative-id":["S0268960X23001042"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101143","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unraveling germline predisposition in hematological neoplasms: Navigating complexity in the genomic era","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101143","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101143"}}